SPARC196.80

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹6,386 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-307.92157.96116.20116.20
Return on Assets-75.18-102.0871.5571.55
Return on Capital Employed-165.85866.78112.12112.12
Return on Invested Capital-250.34-853.5283.8884.86
Margins
EBITDA Margin-532.23-450.2485.0884.68
Operating Margin-548.79-467.5184.5384.53
Incremental Operating Margin-2,092.06106.46
Pretax Margin-512.02-477.6182.6482.96
Net Income Margin-512.52-477.2382.6582.97
Net Income to Common Margin-477.5082.79
FCF Margin-603.19-516.41-13.97-13.97
Additional
Effective Tax Rate-0.100.08-0.01-0.01
Sustainable Growth Rate-307.92157.96116.20116.20
Incremental Operating Margin %-2,092.06106.4661.29
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.